Safety of Terlipressin for Hepatorenal Syndrome

Keyphrases

• 2 Receptor 20%
• A1 Receptor 20%
• Adverse Events 60%
• Atherosclerotic Cardiovascular Disease (ASCVD) 20%
• Blood Pressure 20%
• Duration of Therapy 20%
• Electrolyte 20%
• Hepatorenal Syndrome 100%
• Hypokalemia 20%
• Hyponatremia 20%
• Patient Selection 20%
• Peripheral Ischemia 20%
• Pharmacological Effects 20%
• Randomized Clinical Trial 20%
• Relative Contraindications 20%
• Safety Profile 20%
• Terlipressin 100%
• Unselected Patients 20%
• V1a Receptor 20%
• V2 Receptor 20%
• Vasoconstriction 20%
• Vasopressin 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 60%
• Coronary Artery Atherosclerosis 20%
• Hepatorenal Syndrome 100%
• Hypokalemia 20%
• Hyponatremia 20%
• Randomized Clinical Trial 20%
• Side Effect 80%
• Terlipressin 100%
• Vasopressin V1 Receptor 40%
• Vasopressin V2 Receptor 40%